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Abstract
Similar to other malignancies, urothelial carcinoma (UC) is characterized by specific recurrent chromosomal aberrations and
gene mutations. However, the interconnection between specific genomic alterations, and how patterns of chromosomal
alterations adhere to different molecular subgroups of UC, is less clear. We applied tiling resolution array CGH to 146 cases
of UC and identified a number of regions harboring recurrent focal genomic amplifications and deletions. Several potential
oncogenes were included in the amplified regions, including known oncogenes like E2F3, CCND1, and CCNE1, as well as new
candidate genes, such as SETDB1 (1q21), and BCL2L1 (20q11). We next combined genome profiling with global gene
expression, gene mutation, and protein expression data and identified two major genomic circuits operating in urothelial
carcinoma. The first circuit was characterized by FGFR3 alterations, overexpression of CCND1, and 9q and CDKN2A deletions.
The second circuit was defined by E3F3 amplifications and RB1 deletions, as well as gains of 5p, deletions at PTEN and 2q36,
16q, 20q, and elevated CDKN2A levels. TP53/MDM2 alterations were common for advanced tumors within the two circuits.
Our data also suggest a possible RAS/RAF circuit. The tumors with worst prognosis showed a gene expression profile that
indicated a keratinized phenotype. Taken together, our integrative approach revealed at least two separate networks of
genomic alterations linked to the molecular diversity seen in UC, and that these circuits may reflect distinct pathways of
tumor development.
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Introduction
Cytogenetic and traditional comparative genomic hybridization
(CGH) studies of urothelial carcinoma (UC) have revealed several
recurring chromosomal alterations [1,2,3]. Particularly frequent
are losses of chromosome arms 9p and 9q, amplifications at 6p22,
and deletions of the RB1 tumor suppressor gene on chromosome
13q [4,5]. Array-based CGH (aCGH) studies have been in-
strumental in delineating genomic regions that are targeted by
amplifications and deletions. In an early study, Veltman et al.
identified several candidate oncogenes in recurrent high-level
amplifications, e.g., E2F3 (6p22), CCND1 (11q13), and CCNE1
(19q13) [6]. Subsequent aCGH studies have corroborated these
results and identified several additional recurrent genomic
aberrations, of which, amplifications of the TP53 antagonist
MDM2, and homozygous deletions at 9p21 (CDKN2A), at 10q23
(PTEN), and at 9q33, a region covering the DBC1 gene, are some
examples [7,8,9]. Apart from chromosomal changes, a number of
recurring point mutations have been reported, of which the most
common are activating mutations of the FGFR3 and PIK3CA
genes, as well as inactivating mutations of TP53 and genes
involved in chromatin remodeling [10,11]. The accumulated data
have shown that FGFR3 mutations are characteristic for low grade
and low stage tumors [12] whereas TP53 mutations are
characteristic for invasive tumors. This has lead to the suggestion
that UC develop through at least two molecular pathways, one
related to FGFR3 and one to TP53 [13,14]. In the present
investigation we use tiling resolution aCGH on a series of 146 UCs
and describe a number of putative target genes for recurrent
genomic alterations. We further address the relationship between
impaired TP53 activity, chromosomal instability and level of
genomic rearrangement. Finally, by integration of genomic and
mutation data with gene expression profiling we delineate two
major genomic circuits of central importance for UC develop-
ment.
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Recurrent genomic alterations in urothelial carcinoma
We performed genome wide DNA copy number profiling of
146 cases of UCs using tiling-resolution BAC arrays (Figure 1A).
Genomic regions particularly affected by copy number gains were
observed on chromosome arms 1q, 3p, 3q, 5p, 6p, 8q, 18p, 20p,
and 20q, whereas deletions were common on 2q, 5q, 8p, 9p, 9q,
10q, 11p, 13q, 17p, and 22q (Figure 1B). In line with previous
reports, a strong association between increasing numbers of copy
number alterations and pathological stage and grade was observed
(Figure 1A and Figure S2). Grade 1 tumors carried few alterations:
primarily deletions of 9q, but also occasional deletions of 9p and
gains of 1q whereas G2 tumors showed a slightly wider spectrum
of aberrations. In particular, the frequency of CDKN2A deletions
was increased in G2 compared to G1; 48% vs. 16% (Figure S2A).
A major transition with respect to genomic alterations was
observed between G2 and G3 tumors as G3 tumors harbored
markedly higher numbers of genomic alterations (Figs. 1A and
S2A).
We identified 31 recurrent regions of focal genomic amplifica-
tion (FGA), 16 minimal regions of deletion (MRD), and 7 regions
of recurrent homozygous deletions (HD) (Figure 1B and Table S2).
The most frequent MRDs were seen on chromosome 9 (9p21, and
9q22-q31), followed by 10q23-q25, and 17p13.2. Known tumor
suppressor genes, e.g., CDKN2A (9p21.3), PTEN (10q23), and RB1
(13q14) were located within HD regions, as well as genes with
potential tumor suppressor properties, e.g., CUL3 (2q36.2) and
MGMT (10q26). The most frequent regions of copy number gain
were observed at 1q23 (34%), chromosome arm 5p (27%), 8q22
(29%), and 20q12 (28%) and the three most common FGAs were
observed at 6p22, 11q13, and 8q22. Apart from previously well-
described oncogenes, e.g., E2F3 (6p22), CCND1 (11q13), CCNE1
(19q12), MDM2 (12q15), RAF1 (3p25) FGFR3 (4p14), and ERBB2
(17q12), a number of genes with potential roles in tumor
development were located within FGAs, including SETDB1
(1q21), BCL2L1 (20q11), and members of the YWHA (14-3-3)
gene family (Table S2). We further noticed that the paralogous
genes CCND1 and CCNE1, ID1 and ID2, and YWHAZ, YWHAB,
and YWHAQ, showed alternate amplification patterns resulting in
combined frequencies of 16%, 8%, and 18% respectively.
To visualize associations between genomic imbalances we
performed multidimensional scaling (MDS) on all recurrent
genomic alterations (Figure 2). Moreover, significant associations
(Bonferroni corrected p,0.05, hypergeometric tests) were found
between 19 combinations of aberrations (Figure 2). These analyses
thus highlighted connections between different sets of genomic
imbalances. For example, deletions on 9p, 9q, and 11p were
connected, whereas 6p22 amplifications were associated with
losses on 13q14, 10q, and 20q (Figure 2).
Genomic complexity is associated with global gene
expression patterns
We next aimed to investigate how genomic alterations are
related with gene expression subgroups of UCs. We therefore
stratified tumors into subgroups based on global gene expression
data using hierarchical cluster analysis (HCA; Figure S3A). Two
major clusters of tumors were identified, one dominated by G1/
G2 tumors, split into two subgroups (HC1 and HC2), and
a second, dominated by G3 tumors segregating into three
subgroups (HC3, HC4, and HC5). As expected, the two largest
HCA branches corresponded to the two main molecular subtypes
(MS) previously described for bladder cancer [15]; MS1 tumors
were confined to HC1 and HC2 whereas HC3, HC4, and HC5
were of the MS2 type (Figure 3A).
We then used two measures to estimate levels of genomic
complexity: the total number of FGAs (nFGA) and the fraction of
altered BAC clones (fBAC). Both parameters showed a strong
association with the gene expression clusters (Figure 3A and 3B).
In our cohort, 56% of the samples carried either non-synonymous
mutations in TP53, or showed amplification or overexpression of
MDM2, which targets TP53 for degradation (Figure S4A). We
have previously shown that TP53/MDM2 alterations are not
strictly associated with genomic instability (15), and in the present,
extended series of tumors, neither nFGA, nor fBAC, were
significantly associated with TP53/MDM2 status within each MS
subtype (Figure 3C). When, however, these measures were
compared between MS1 and MS2 tumors within TP53/MDM2
altered and wild type cases separately, significant associations with
MS subtype was observed (Figure 3C). Hence, genomic complex-
ity shows a stronger association with MS type than with TP53/
MDM2 status. We then used a gene expression signature for
chromosome instability (CIN) [16] and calculated a CIN gene
expression score for each tumor. The CIN genes showed a clear
association with HCA clusters (Figure 3A) and correlated
significantly with both nFGA (r=0.58) and with fBAC (r=0.54).
Moreover, a significant increase in CIN score was observed for
tumors with FGAs and for tumors with increased fBAC
(Figure 3D). However, no difference in scores was noted between
cases with few or many FGAs, or between cases with medium or
high fBAC. Importantly, both the CIN score and the presence of
FGAs were associated with adverse patient survival (Figs. 3E and
3F).
Molecular subgroups of UC are characterized by distinct
genomic alterations
The results presented in Figure 2 suggested that two separate
branches of interconnected genomic alterations may be present in
UCs. To explore this finding further, we identified recurrent
genomic aberrations that were significantly associated (Bonferroni
corrected p,0.05, Fisher’s tests) with the five gene expression
subgroups shown in Figure 3A. Ten focal events (FGAs, HDs or
MRDs) and six large chromosome arm alterations were signifi-
cantly associated with specific HCA groups (Figure 4A). The most
common chromosomal alteration in HC1 was deletions on whole
or large segments of 9q (50%). HC2 tumors showed frequent losses
on both 9p and 9q, and a high frequency (65%) of hemizygous/
homozygous CDKN2A deletions. HC1 and HC2 also displayed
a high prevalence of FGFR3 and PIK3CA mutations (Figure 4A),
and consistent high FGFR3 and CCND1 expression (Figure 4B).
However, genomic amplifications of CCND1 were associated with
HC4 (7 of 17 HC4 cases; Figure 4A).
More than half (60%) of samples in HC5 harbored 6p22
amplifications. In addition, deletions of the RB1 locus were
frequent (65%) and accompanied by reduced RB1 gene expression
(Figs. 4A and 4B). A closer inspection revealed that three
additional HC5 cases carried intra-chromosomal breakpoints
surrounding the RB1 locus (Figure S5). Thus, almost all tumors
(95%) in HC5 harbored genomic alterations at 6p22 and/or
13q14, strongly indicative for a hyper-activation of the E2F
pathway. This was further supported by increased expression of an
E2F3 gene signature described by Bild et al. [17] (Figure 4B).
Moreover, by organizing tumors within each HCA cluster
according to FGFR3 expression, a subset of HC3 tumors (HC3c)
with low FGFR3 expression that showed 6p22 amplifications and/
or RB1 losses in close to 70% of the cases, along with increased
expression of the Bild E2F3 signature. This was contrasted by the
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CDKN2A alterations, within which only 11% of the samples carried
6p22 and/or RB1 alterations (Figure S5). Interestingly, 6p22 and
RB1 alterations were associated with a relative overexpression of
CDKN2A (Figs. 4B and S6A). This observation was further
corroborated by an immunohistochemical analysis of p16 protein
expression using tissue microarrays (TMA) comprising 119 of the
samples. 6p22/RB1 altered tumors showed significantly higher
Figure 1. DNA copy number alterations in 146 bladder tumors. A) Whole genome heatmap representing relative copy number profiles of the
samples. Segments of gains or deletions are color-coded according their relative log2 copy number ratios. B) DNA copy number frequency plot of
gains (red) and losses (blue). Above: Recurrent high-level focal amplifications (FGA; red) are indicated by red bars and labeled according to their
cytogenetic localization. Below: Recurrent homozygous deleted regions (HD; blue) and recurrent minimal regions of deletions (MRD; green) labeled
according to their respective cytogenetic localization.
doi:10.1371/journal.pone.0038863.g001
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without 6p22/RB1 alterations (p,0.0001, t-test; Figs. S6B–6E).
Our data further suggested the presence of a specific RAF1/RAS
related group of tumors as 5 out of 7 RAF1 amplified tumors
localized to a subset of HC3 tumors with moderate FGFR3
expression (HC3b) and the majority of RAS mutated tumors
formed a subgroup within HC2 (HC2b). Only one tumor in these
two subgroups harbored an FGFR3 mutation and no over-
expression of FGFR3 was observed. In fact, RAF1/RAS alterations
showed a significant negative association with FGFR3 mutations
(p,0.002, hypergeometric test) suggesting that these alterations
may be complementary to each other.
Two genomic circuits in urothelial carcinoma
The above analysis led us to refine the subgrouping of tumors
into groups that share central features of gene expression, genomic
alterations, and gene mutation data (Figure 4C). Two of the
groups, HC1 and HC2a/HC3a, respectively, were highly
enriched for FGFR3 mutations, high CCND1 expression, and 9q
deletions. However, for HC2a/HC3a tumors the frequency of
CDKN2A deletions was drastically increased, suggesting that
acquisition of CDKN2A deletions occurs later during tumor
progression than for example FGFR3 mutations and 9q deletions.
The tumors in HC3c and HC5 did, on the other hand, seem to
depend on alternative genomic and genetic alterations as
suggested by the high incidence of 6p22 amplifications and RB1
deletions, and the near absence of both FGFR3 mutations and
CDKN2A deletions (Figure 4C). These observations were sub-
stantiated by immunohistochemical analysis of FGFR3, CCND1,
p16, E2F3, and RB1 protein expression in 119 matched samples
using TMA (Figure 5A). Protein expression of these markers for
two representative samples of the HC1 and HC5 subgroups,
respectively, is illustrated in Figure 5B.
The skewed distribution of genetic and genomic alterations
between UC subgroups indicated the presence of at least two,
Figure 2. Associations between chromosomal aberrations visualized by MDS. Recurrent FGAs, HDs, and MRDs, as well as recurrent large
chromosome arm deletions were included in the analysis. FGAs and HDs present in ,5% of samples were excluded. Aberrations with significant
positive associations, as determined by hypergeometric tests, are indicated in red and connected with green lines. Aberrations located to the same
chromosomes are circled in gray for visualization purposes.
doi:10.1371/journal.pone.0038863.g002
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we performed pairwise hypergeometric tests between all aberra-
tions that were associated with gene expression subclusters.
Furthermore, to be able to include gene expression in this analysis,
FGFR3 expression were categorized in to high, intermediate, and
low expression, and CCND1, RB1, PTEN, CDKN2A, and RAF1 into
low and high expression (Figure S4B). In Figure 6A the results are
given in the form of a simplified network model. This analysis
Figure 3. Genomic complexity is associated with UC gene expression subtypes. A) Hierarchical cluster analysis (HCA) on gene expression
data segregated the tumors into five clusters, HC1 to HC5. Samples within each HCA group are ordered according to their relative FGFR3 expression
(high expression left, low expression right). For each individual tumor, molecular signature (MS) type, pathological grade, stage, nFGA, fBAC, and
TP53/MDM2 status is indicated. The relative expression levels for genes within the CIN signature are indicated by a heatmap below (green, low
expression; red high expression). B) Boxplot illustrating the number of FGAs (nFGA) and frequency of genomic imbalances (fBAC) for samples within
each HCA group. C) Boxplot of nFGA (left) and fBAC (right) for tumor samples when grouped on TP53/MDM2 status and MS type. P-values obtained
by Wilcoxon statistics. n.s., not significant. D) Boxplot illustrating increased CIN score for samples with increased nFGAs (left) and fBAC (right). P-
values obtained by ANOVA. E and F) Disease specific survival (DSS) analysis with tumors grouped according to nFGAs (0 vs $1 FGA) and CIN pathway
score (above or below median), respectively.
doi:10.1371/journal.pone.0038863.g003
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CCND1 expression, CDKN2A deletions, and deletion 9q as one
circuit (the FGFR3/CCND1 circuit). The other circuit, the E2F3/
RB1 circuit, was defined by 6p22 amplifications, deletions of RB1,
PTEN, 5q, 2q36, 22q, and 16q, and gains of 5p, accompanied by
reduced expression of FGFR3, RB1, and PTEN, and high
expression of CDKN2A. The analysis also suggested the presence
of a RAF1/RAS route, complementary to FGFR3 mutations;
however, this circuit did not attain statistical significance, possibly
due the relative low frequency of these alterations.
We finally performed a survival analysis with the refined group
definitions inferred in Figure 4C. No patients within the HC1
group succumbed to the disease during the time of follow up
(Figure 6B). An adverse outcome was however observed for
patients within the HC2a/HC3a group. Similarly, decreased
survival rates were observed for the two groups enriched with
RAF1/RAS and 6p22/RB1 alterations. However, the worst
outcome was noted for HC4 patients, which, except for
a significant enrichment of CCND1 amplifications and a high rate
of TP53/MDM2 alterations, were heterogeneous with respect to
the setup of genomic alterations. Also, tumors within this group
were less genomically complex than the HC5 subgroup (Figure 3B).
We therefore used gene expression data to identify genes with
significant upregulation in HC4 relative to the other gene
expression clusters. The obtained gene signature was highly
enriched for genes that indicate a keratinized phenotype, such as
KRT6A, KRT6B, KRT6C and KRT16, as well as SPRR1B, SPRR2A,
SPRR2D, and SPRR2F. Importantly, a histopathological reevalua-
tion corroborated these findings: 7 of the 17 HC4 tumors showed
signs of squamous differentiation. Thus, our data stress a subgroup
of UCs with diverse setup of underlying genomic alterations, but
with an expressional program connected to keratinization, that is
associated with a highly unfavorable prognosis.
Discussion
In this study, we performed an integrated analysis of genomic
alterations, gene expression, and gene mutation data on a large
series of urothelial carcinomas. To start with, we defined
Figure 4. Integrated analysis of genomic alterations, gene mutations, and gene expression data. A) Recurrent genomic alterations with
significant association to gene expression subtypes. Activating mutation of FGFR3, PIK3CA, and RAS, and inactivating mutations of CDKN2A, as well as
amplifications of FGFR3 and RAF1, and TP53/MDM2 status is also displayed. Within each HCA group, samples are ordered according to their relative
FGFR3 expression. Dashed vertical lines, which define subsets within each HCA group, are drawn with respect to the E2F3, RB1, 5p, RAF1, and RAS
alterations pattern and FGFR3 expression. Amplifications and homozygous deletions are indicated in black. Gains and deletions are indicated in gray.
Activating/inactivating mutations are indicated in black. B) Heatmap representing relative expression levels of selected genes and the Bild E2F3
signature [17]. Green, low expression; red high expression. C) Frequencies of selected genomic alterations in gene expression subgroups.
doi:10.1371/journal.pone.0038863.g004
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genomic alterations. In line with previous data, we observed
recurrent amplifications (FGAs) at, e.g., 6p22 (E2F3), 11q13
(CCND1), 8q22 (YWHAZ), 3p25 (RAF1), 4p16.3 (FGFR3), 12q15
(MDM2), and 17q12 (ERBB2), to mention some. We also identified
several novel genes and chromosomal regions of possible
importance for UC tumorigenesis. For example, a common region
of amplification at 1q21.2 included the histone methyltransferase
SETDB1, which has been implicated in the onset of melanomas
[18], and the apoptotic regulator BCL2L1 at 20q11 was also found
recurrently amplified. Notably, we found several instances of
amplifications of paralogous genes. For example, a large fraction
(18%) of the tumors showed genomic amplification of either
YWHAZ, YWHAB,o ro fYWHAQ. The CDKN2A locus was by far
the most frequent homozygous deleted (HD) locus in our data.
However, HDs were also observed for the well-known tumor
suppressor genes PTEN and RB1. Interestingly, we observed HDs
that involved the DNA methyltransferase MGMT (10q23) and the
CUL3 gene (2q36.2), that may be possible targets for the frequent
deletions observed at 2q and 10q. The recurrent regions of
deletion (MRDs) were typically wide, thus resulting in large
numbers of potential target genes. For example, we were able to
narrow down a region on 9q that, among others, included the
PTCH1 gene that previously has been postulated as a UC specific
tumor suppressor gene [19]. However, this region also contained
the XPA gene, important for DNA excision repair, and implicated
in neoplastic transformation.
We next estimated the level of genomic complexity for the
tumors based on chromosomal alterations (nFGA and fBAC), as
well as indirectly using a published gene signature for chromo-
somal instability (CIN; 20). These genomic complexity measures
were analyzed in relation to matched global gene expression
profiling data and TP53/MDM2 alteration status. Through this
approach we could extend our observations from a previous study
[15] in that the link between genomic complexity and the two
intrinsic molecular subtypes of UC (MS1 and MS2) is stronger
than what is observed between genomic complexity and TP53/
MDM2 alterations. That is, MS2 cases wild type for TP53/MDM2
show as rearranged genomes as mutated cases. In contrast, MS1
cases, with or without TP53/MDM2 alterations, show significantly
lower levels of genomic complexity. Based on these findings we
hypothesize that TP53/MDM2 alterations have different biological
Figure 5. Validation of gene expression data by IHC on tissue microarray. A) Barplots summarizing tumor cell protein scores of selected
proteins in tumors stratified according to the gene expression subtypes. Error bars represent 6SEM. B) IHC stainings of two representative HC1 (top)
and HC5 samples (bottom).
doi:10.1371/journal.pone.0038863.g005
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TP53/MDM2 alterations may primarily function to promote
protection from oncogenic stress signals [20]. The presence of
these alterations in MS2 cases may, on the other hand, indicate
selection of cells resistant to apoptotic signals associated with
genomic instability. Therefore, TP53/MDM2 alterations do not
have to be causative for genomic instability per se. We also
compared the CIN signature between tumors with increasing
number genomic alterations. A major transition was observed
between tumors with low numbers of aberrations as compared to
tumors with intermediate levels. However, no significant difference
was seen between the groups of intermediate as compared to high
numbers of genomic alterations. Taken together, our findings
indicate that UC may be categorized into tumors with simple and
with complex genomes, i.e. into tumors that have passed through
a period of genomic instability and tumor that have not, and that
this distinction does not seem directly dependent on the presence
of TP53/MDM2 alterations.
The high prevalence of FGFR3 mutations seen in non-invasive
tumors is contrasted by infrequent mutations of this gene within
the group of muscle invasive tumors. Moreover, invasive cancers
often present without history of non-invasive disease. It has
therefore been suggested that UCs may arise through at least two
divergent molecular pathways: one associated with FGFR3 and
the other with TP53 and RB1 alterations [13,14]. However,
details regarding cooperative alterations within these suggested
pathways are far from clear. In order to elucidate these matters, we
used matched global gene expression to cluster our samples into
distinct molecular subgroups. We then used stringent statistical
tests to identify genomic alterations that were associated with the
obtained molecular phenotypes. Using this approach we could
define two main genomic circuits in UC. Central alterations within
these circuits were alterations of FGFR3/CCND1 and E2F3/RB1,
respectively, with several additional alterations linked to each of
the two routes. Our analyses also suggested that RAF1 and RAS
alterations, which were found in a near mutual exclusive manner
to FGFR3 mutations, defined a possible third but less well
established route.
In the first circuit, a strong link between FGFR3 hyperactivation
and overexpression of CCND1 was noted, indicating that these
tumors are receptor pathway driven through activation of the early
G1 phase of the cell cycle. Moreover, tumors within this circuit
segregated into two molecular phenotypes: both of which
harbored frequent 9q deletions, 1q gains and PIK3CA mutations,
but with CDKN2A deletions almost exclusively observed in the
group with increased numbers of genomic alterations and a worse
survival. We therefore suggest that CDKN2A inactivation occurs
secondary to 9q deletions in the FGFR3 circuit. In this scenario
CDKN2A loss is coupled to tumor progression rather than
initiation, perhaps by further promoting a CCND1 driven
activation of the cell cycle G1 phase of the cell cycle.
Two major components of the second circuit were amplifica-
tions of the E2F3 locus at 6p22 and reduced RB1 expression. Our
data thus corroborate the close link between 6p22 amplifications
and RB1 inactivation observed in UCs by Hurst et al. [21]. The
importance of E2F3 induced gene expression was shown by
consistent overexpression of the E2F3 Bild et al. gene signature in
E2F3/RB1 associated cases. E2F3 expression in combination with
low RB1 expression indicates that these tumors, in contrast to the
FGFR3/CCND1 tumors, may be independent of the G1 re-
striction point and instead driven by the late G1 phase of the cell
cycle. Additional changes within the E2F3/RB1 circuit included,
among others, 10q deletions and 5p gains. Interestingly, reduced
PTEN expression was specific for the E2F3/RB1 group in contrast
to PIK3CA mutations that associated with the FGFR3 circuit. In
fact, a significantly lower PTEN expression was observed for
tumors without PIK3CA mutation. Our data thus suggest that
acquired alterations of PIK3CA and PTEN are complementary and
may in fact be subtype specific in UC. This is in line with data
from a recent study of transgenic mice that demonstrated that
concurrent inactivation of pten and tp53 in mouse bladder
epithelium led to invasive tumor growth [22]. In most published
Figure 6. Genomic networks and survival analysis of genomic subtypes. A) MDS plot based on the subset of genomic alterations (Figure 4A)
and categorized gene expression data (Figure S3B) that showed at least one instance of significant positive or negative association in a pair-wise
hypergeometric tests. Green lines, significant positive association; red lines, significant negative association. B) Kaplan-Meier analysis of tumors
grouped according to a combination of gene expression and genomic alteration patterns using disease specific survival (DSS) as endpoint.
doi:10.1371/journal.pone.0038863.g006
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and often the entire chromosome arm [4,9,14]. Consequently, no
obvious 5p target genes have been identified. Irrespectively, the
association of 5p with high grade and invasive tumors has been
repeatedly reported and we show that 5p may be an integral part
of the aggressive phenotype observed for tumors in this circuit.
The finding that the E2F3/RB1 circuit was specifically
associated with low FGFR3 expression indicates this circuit as
essentially different from FGFR3/CCND1 tumors. Furthermore,
E2F3/RB1 cases rarely evolve from FGFR3/CCND1 tumors as
very few of the former harbor FGFR3 or PIK3CA mutations, and in
particular, do not harbor homozygous deletions of CDKN2A. Thus,
our data suggest the presence of two complementary pathways
operating in UC, one characterized by FGFR3/CCND1 and
a second by the E2F3/RB1 alterations. We also demonstrated that
E2F3/RB1 altered tumors show overexpression of CDKN2A,
which, at first hand, may be surprising. However, these tumors are
most likely less sensitive to CDKN2A levels due to the aberrant
E2F3/RB1 expression, and may thus tolerate a stronger p16
induced senescence signal.
We finally identified a gene expression subgroup of high grade
tumors which was relatively heterogeneous with respect to the
chromosomal alterations that defined the above genomic circuits.
This group of tumors showed no distinct pattern of genomic
alterations, except for enrichment of CCND1 amplifications.
Intriguingly, this group had the worst prognosis. A clue to the
nature of these tumors was obtained by gene expression analysis;
increased expression of genes associated with keratinization was
observed, thus suggesting signs of squamous metaplasia. Impor-
tantly, these findings were corroborated by a subsequent patho-
logical reevaluation. Hence, these tumors may have acquired
additional genomic and/or epigenetic hits that promote a squa-
mous like phenotype. However, the relatively low frequency of
these tumors implies that a larger sample material is needed to
describe this circuit further.
Materials and Methods
Sample acquisition and mutation analyses
Urothelial carcinomas were collected by cold-cup biopsies from
the exophytic region of the bladder tumor in 146 patients
undergoing transurethral resection at the Department of Urology,
Ska ˚ne University Hospital, Sweden. Written informed consent was
obtained from all patients, and the study was approved by the
Local Ethical Committee of Lund University. Follow up data was
available for 145 of the patients (median follow-up time 56
months). RNA was isolated using Trizol (Invitrogen) and purified
on Qiagen RNeasy columns (Qiagen). RNA sample integrity was
assessed on an Agilent 2100 Bioanalyzer (Agilent technologies).
Genomic DNA was extracted using the DNeasy Tissue kit
protocol (Qiagen) or using the organic phase of the Trizol lysate
according to the manufacturers instructions. Mutation status for
FGFR3, PIK3CA, KRAS, HRAS, NRAS, CDKN2A, and TP53 were
determined by direct sequencing as described in Sjo ¨dahl et al. [11]
(Table S1). Patient data is summarized in Table 1 and detailed
sample information and mutation data are given in Table S2.
Genomic profiling and gene expression analyses
Genomic DNA was hybridized to 32K BAC arrays produced at
the SCIBLU Genomics Centre (http://www-lth.se/sciblu) at
Lund University. Genomic profiles for 36 samples were included
in Heidenblad et al. [9]. Hybridization, data normalization, and
segmentation were performed as described previously [9,15].
Gene expression profiling was performed using Illumina
humanHT12v3 BeadChips (Illumina Inc) on 131 samples from
which total RNA was available. Samples were randomly
distributed into two separate labeling batches. To correct for
labeling specific biases, raw intensity values were subjected to
a labeling specific transformation step, in which for each probe on
the array, the geometric mean of signal intensities for samples in
the second batch was scaled to the geometric mean of samples on
the first labeling batch. Intensity values were then background
corrected, negative values were capped to zero, and an intensity
constant of 30 was added to all probe intensities. Data were
normalized using a quantile normalization algorithm as imple-
mented in BASE [23], log2 transformed, and variance filtered
(SD.0.25). Raw data files as well as filtered and normalized data
matrixes are supplied on the NCBI GEO web site (http://www.
ncbi.nlm.nih.gov/geo/) through accession number GSE32549.
Identification of copy number alterations
Genomic gains and deletions were defined from segmented log2
data using sample adaptive thresholds (SAT) on 250 kb smoothed
data [24]. High-level focal genomic amplifications (FGAs) and
homozygous deletions (HDs) were defined as segmented log2
ratios $0.8 or #20.8, respectively, and only segments longer than
three consecutive BAC probes were considered. FGAs less than
1 Mbp apart were considered as one single amplicon when
calculating FGA frequencies. Recurrent FGAs were defined as
genomic segments for which at least three samples were amplified,
recurrent HDs as regions for which at least two samples were
altered, and minimal regions of deletions (MRD) were defined by
a minimum of 15 cases, as outlined in Figure S1. Recurrent
aberrations were crosschecked against known copy-number
variants (CNVs) available through the Copy Number Variation
Project (http://www.sanger.ac.uk/humgen/cnv/data/cnv_data/)
and the Database of Genomic Variants (http://projects.tcag.ca/
Table 1. Summary of patient material.
Tumor Stage (n)
Ta 49
T1 53
$T2 42
Tx 1
Tis 1
Tumor Grade (n)
G1 19
G2 46
G3 81
Median age, years (range) 70 (38–90)
Gender (n)
Female 32
Male 114
Mutation frequencies (%)
FGFR3 38.4
PIK3CA 16.7
RAS 6.2
TP53 39.7
CDKN2A 1.9
doi:10.1371/journal.pone.0038863.t001
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from further analyses. Large recurrent chromosome arm gains and
losses were defined as cases in which .50% of BAC probes for
a chromosome arm were above or below the respective SAT level
in more than 10% of the samples.
Immunohistochemistry
Tissue microarray (TMA) blocks were constructed from 1.0 mm
punches of formalin fixed paraffin embedded tissue specimens. All
cores were selected by a pathologist to contain sufficient tumor
material for scoring of tumor cells. 119 tumors were represented
on the TMAs. Two cores per sample were included, except for 3
samples that were represented by a single core. Monoclonal
antibodies against FGFR3 (clone C51F2, Cell Signaling), CCND1
(clone SP4, Dako), RB1 (clone 4H1, Cell signaling), E2F3 (clone
3E2F04, Labvision), p16 (clone G175-405, BD biosciences) were
used. TMA sections were pretreated using Dako PT Link pH 9,
stained using Dako Autostainer, and visualized using Dako
EnVision
TM
FLEX K8010 (Dako). As negative control, the primary
antibody was omitted. Staining intensities were assigned a score of
0–3 and the fraction of positive tumor cells/nuclei was estimated
using 10% intervals (0%–100%). The tumor cell protein score was
calculated by multiplying the intensity with the fraction of positive
tumor nuclei. For samples represented by two cores, the mean
score was used.
Statistical analyses
Statistical analyses were performed using the R software
(http://www.r-project.org). Multidimensional scaling (MDS) was
performed using Jaccard distances based on the presence or
absence of recurrent alterations. FGA regions present in limited
number of samples (,5%) were not included in these analyses.
Hierarchical Cluster Analyses (HCA) was performed using
Pearson correlation and Ward’s method for agglomeration.
Survival curves were compared using Kaplan-Meier estimates
and disease specific survival (DSS) was used as end point.
Differential gene expression between sample groups was de-
termined using the limma R package [25] and Bonferroni
corrected p-values,0.05 were considered significant.
Supporting Information
Figure S1 Schematic illustration on how recurrent focal
genomic amplifications (FGAs), homozygous deletions
(HDs), and minimal regions of deletion (MRDs) were
defined from segmented genomic profiles of 146 tumors.
Orange horizontal bars above the ideogram represent samples
with segments of amplification (relative copy number log2.0.8).
Blue bars below the ideogram illustrate samples with deletions
(log2,SAT) and dark blue bars represents segments of homozy-
gous deletion (log2,20.8). For recurrent FGA regions a minimum
of 3 samples had to show amplification. For MRDs the limit was
set to 15 cases and for HDs a minimum of 2 cases. First, core
regions were defined representing local peak maxima (black
vertical lines), i.e. the minimal shared chromosomal region for
amplifications, deletions, and homozygous deletions, respectively
(indicated by black arrowheads). To allow for uncertain measure-
ments due to technical noise, the boundaries for each core region
was increased to include two cases less altered than the maximum
number of altered cases for that region (red arrowheads and red
vertical lines). For HDs this limit was set to one sample less than
the maximum number. In cases of overlap between MRD and HD
regions, the region defined by HD boundaries was used. Recurrent
aberrations were crosschecked against known copy-number
variants (CNVs) available through the Copy Number Variation
Project and the Database of Genomic Variants, and regions with
high CNV overlap were removed from further analyses. In some
instances, regions of deletions were too large to accurately define
MRDs. For example, most samples carried whole or near whole
arm deletions of 5q and the only MRD peak that could be
identified corresponded to a known CNV (visible in Fig. 1B).
Therefore no MRDs were defined on this chromosome arm.
Instead we used a measure to include large and recurrent deletions
of chromosome arms. The large gains and losses were defined as
cases in which .50% of BAC probes for a chromosome arm were
above or below the respective SAT level and were defined as
recurrent present in more than 10% of the samples.
(TIF)
Figure S2 DNA copy number frequency plot of gains
(red) and losses (blue). Tumors are stratified according to A)
grade and B) stage, respectively. The presence of gains and
deletions were defined from the segmented log2 data using sample
adaptive thresholds (SAT) on 250 kb smoothed data [24].
(TIF)
Figure S3 Hierarchical cluster analysis (HCA) based on
global gene expression. The analysis was performed on
a variance filtered expression matrix (SD.0.25) Representing
relative transcript levels for 18997 reporters in 131 tumors.
(TIF)
Figure S4 Gene expression rank plots. Relative gene
expression (y-axis) obtained from global gene expression analysis
of 131. Samples are ordered from the lowest expressing sample to
the highest expressing sample (x-axis). A) MDM2 gene expression.
Samples with TP53 mutation or MDM2 amplifications are
indicated with red lines and red solid circles, respectively. Samples
with expression above the horizontal dashed line were considered
to overexpress MDM2. B) Rank plots used to define categorized
variables for FGFR3, CCND1, RAF1, CDKN2A, PTEN, and RB1
gene expression levels. For CCND1, RAF1, and CDKN2A, samples
with elevated expression relative to the dashed red horizontal line
were considered CCND1
high RAF1
high, and CDKN2A
high, respec-
tively. For PTEN and RB1, samples with lower expression than
indicated by the dashed line were defined as low expressers
(PTEN
low and RB1
low, respectively). FGFR3 expression was divided
into FGFR3
high and FGFR3
low expression (above or below the two
dashed lines, respectively).
(TIF)
Figure S5 Genomic alterations at three chromosome
arms for samples in the HC5, HC3c, and HC2 sub-
groups. The RB1, E2F3, and CDKN2A loci are indicated by
vertical lines. Three HC5 samples harbor intrachromosomal
breakpoints surrounding the RB1 locus (arrowheads). Segments of
genomic imbalances are color-coded as follows: amplifications
(red), gains (orange), no alteration (gray), deletions (blue), and
homozygous deletions (dark blue).
(TIF)
Figure S6 Relative mRNA transcript levels and protein
expression of the CDKN2A gene. A) Rank plot of CDKN2A
gene expression. Samples with 6p22 amplifications and/or RB1
deletions are colored in red. Samples with homozygous deletions
at the CDKN2A locus are indicated with blue lines. B) Relative p16
protein expression in normal urothelium (n=3), as well as for
tumors with no detected E2F3 amplification or RB1 deletion
(n=84) and tumors with E2F3 amplification and/or RB1 deletion
(n=35), as assessed using TMA. Protein expression was calculated
by multiplying the intensity with the fraction of positive tumor cell
Genomic Profiling of Bladder Cancer
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used. C–E) Representative IHC stainings of p16 protein
expression in C) normal urothelium D) tumors without amplifi-
cation of E2F3 or RB1 deletions, and E) tumors with E2F3
amplification.
(TIF)
Table S1 List of recurrent regions of focal genomic
amplification (FGA), deletions (MRD) and homozygous
deletions (HD). For each region, the corresponding cytoband,
genomic position, and start and end BAC reporter is given.
(XLSX)
Table S2 Detailed sample information for the 146
tumors included in the study. The TNM 2002 and WHO
1999 classification systems were used for tumor staging and
grading, respectively. DOD, dead of disease. NA, data not
available.
(XLS)
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